A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery.

Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) --  Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced that it has filed a new U.S. divisional patent application with the United States Patent and Trademark Office (USPTO), further expanding the Company’s intellectual property portfolio relating to its proprietary mucoadhesive technology.

The divisional application, titled "Mucoadhesive Polymers for Nasal Drug Delivery," was assigned U.S. Patent Application No. 19/823,285.

The new application is part of Polyrizon’s broader patent family covering its proprietary mucoadhesive polymer technology. The technology is based on polymeric compositions designed for application to mucosal surfaces and capable of forming a continuous and durable layer upon contact with mucosal tissue.

The underlying technology is designed to support a range of potential applications, including the use of mucoadhesive formulations as a platform for the local or systemic delivery of therapeutic agents through mucosal tissues, including the nasal mucosa. The patent family describes the potential incorporation of therapeutic active ingredients into the mucoadhesive compositions, providing a technological foundation for the development of intranasal drug delivery systems.

The divisional filing enables Polyrizon to pursue additional patent protection for distinct aspects and applications of its technology while maintaining its connection to the Company’s existing U.S. patent family.